Recently, based on two phase I/II trials (NCT03157128 and NCT03037385), selpercatinib (Retevmo) and pralsetinib (Gavretotm) have been approved for RET‐positive advanced NSCLC.80, 81. This evidence concerns the gene RET and non-small cell lung carcinoma.